ELI LILLY & CO

Discover how Eli Lilly’s record Q3 earnings and a Medicare price‑cut deal for weight‑loss drugs are propelling the company’s stock and reshaping the U.S. obesity‑drug market.

Eli Lilly & Co.’s stock price declined sharply after a study revealed disappointing results for its experimental weight-loss pill, Orforglipron.

Eli Lilly & Co. reported a first-quarter earnings miss, sending its stock plummeting, amidst intense competition and strategic challenges in the weight-loss drug market.